Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYCLaura A. Sena, Samuel R. Denmeade|Journal of Clinical Investigation|2022Cited by 44
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC)David R. Wise, Kwok‐Kin Wong, Samuel R. Denmeade et al.|Prostate Cancer and Prostatic Diseases|2024Cited by 9